SK Bioscience builds a vaccine production facility in Serbia
김지선
stockmk2020@alphabiz.co.kr | 2023-09-11 03:00:52
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Bioscience has joined hands with the Serbian government for vaccine development and production cooperation. It plans to build a vaccine production base in Serbia to make it a stepping stone to enter the European market.
SK Bioscience announced on August 8 that Serbian Prime Minister Ana Brnabić visited the headquarters in Pangyo, Gyeonggi-do, and signed a memorandum of understanding (MOU). SK Bioscience is the only domestic pharmaceutical and bio company visited by Prime Minister Brenavic, who visited Korea for the first time in 13 years since 2010.
The Serbian government, SK Bioscience and Frontier Biopharma will sign a detailed contract by the end of this year based on MOU and start establishing and commercializing vaccine production facilities in Serbia.
The Serbian government, along with administrative support for the project, cooperates to ensure that finished products are quickly procured in Serbia. Frontier Biopharma will take charge of the overall operation of the project.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 4NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 5Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 6Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure